Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections

Jae Hyang Lim; Brigid Stirling; Jonathan Derry; Tomoaki Koga; Hirofumi Jono; Chang Hoon Woo; Haodong Xu; Patricia Bourne; Un Hwan Ha; Hajime Ishinaga; Haidong Xu; Ali Andalibi; Xin Hua Feng; Hongguang Zhu; Yuxian Huang; Wenhong Zhang; Xinhua Weng; Chen Yan; Zhinan Yin; David E. Briles; Roger J. Davis; Richard A. Flavell; Jian Dong Li

doi:10.1016/j.immuni.2007.07.011

Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections

Jae Hyang Lim, Brigid Stirling, Jonathan Derry, Tomoaki Koga, Hirofumi Jono, Chang Hoon Woo, Haodong Xu, Patricia Bourne, Un Hwan Ha, Hajime Ishinaga, Haidong Xu, Ali Andalibi, Xin Hua Feng, Hongguang Zhu, Yuxian Huang, Wenhong Zhang, Xinhua Weng, Chen Yan, Zhinan Yin, David E. BrilesRoger J. Davis, Richard A. Flavell, Jian Dong Li

Department of Microbiology

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Abstract

Streptococcus pneumoniae (S. pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute lung injury (ALI). The molecular mechanisms underlying ALI and the high early mortality remain unknown. Despite recent studies that identify deubiquitinating enzyme cylindromatosis (CYLD) as a key regulator for T cell development, tumor cell proliferation, and NF-κB transcription factor signaling, its role in regulating bacteria-induced lethality, however, is unknown. Here, we showed that CYLD deficiency protected mice from S. pneumoniae pneumolysin (PLY)-induced ALI and lethality. CYLD was highly induced by PLY, and it inhibited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, thereby potentiating ALI and mortality. Thus, CYLD is detrimental for host survival, thereby indicating a mechanism underlying the high early mortality of pneumococcal pneumonia.

Original language	English
Pages (from-to)	349-360
Number of pages	12
Journal	Immunity
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.immuni.2007.07.011
State	Published - 24 Aug 2007

Bibliographical note

Funding Information:
We are grateful to Drs. R. Malley and A. Srivastava for kindly providing the purified native PLY and Dr. G. Mosialos for kindly providing anti-CYLD antibody. We also thank Drs. R. Bernards and J. Han for kindly providing various expression plasmids. Out thanks also extend to Dr. R. Malley for his helpful input and discussions regarding the manuscript and Dr. G. Mosialos for critically reviewing this manuscript. This work was supported in part by grants from National Institute of Health DC005843 and DC004562 and a start-up fund from University of Rochester Medical Center (to J.-D.L.), Major State Basic Research (973) Program (2005CB523102), China (to W.Z. and X.W.), Arthritis Foundation Investigator Award, National Institute of Arthritis and Musculoskeltal and Skin Disease Grant KO1 AR 02188, National Institute of Health Grants RO1AI56219 (to Z.Y.), HL077789 and AHA EIA0740021 (to C.Y.) and by Amgen. RJD and RAF are investigators of the Howard Hughes Medical Institute. We declare that a patent on using recombinant PAI-1 for the treatment of lethal bacterial infections has been filed by University of Rochester.

Keywords

CELLIMMUNO
HUMDISEASE
MICROBIO

Access to Document

10.1016/j.immuni.2007.07.011

Cite this

Lim, J. H., Stirling, B., Derry, J., Koga, T., Jono, H., Woo, C. H., Xu, H., Bourne, P., Ha, U. H., Ishinaga, H., Xu, H., Andalibi, A., Feng, X. H., Zhu, H., Huang, Y., Zhang, W., Weng, X., Yan, C., Yin, Z., ... Li, J. D. (2007). Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections. Immunity, 27(2), 349-360. https://doi.org/10.1016/j.immuni.2007.07.011

@article{50861f9998c740c98e0f0d3f922888f6,

title = "Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections",

abstract = "Streptococcus pneumoniae (S. pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute lung injury (ALI). The molecular mechanisms underlying ALI and the high early mortality remain unknown. Despite recent studies that identify deubiquitinating enzyme cylindromatosis (CYLD) as a key regulator for T cell development, tumor cell proliferation, and NF-κB transcription factor signaling, its role in regulating bacteria-induced lethality, however, is unknown. Here, we showed that CYLD deficiency protected mice from S. pneumoniae pneumolysin (PLY)-induced ALI and lethality. CYLD was highly induced by PLY, and it inhibited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, thereby potentiating ALI and mortality. Thus, CYLD is detrimental for host survival, thereby indicating a mechanism underlying the high early mortality of pneumococcal pneumonia.",

keywords = "CELLIMMUNO, HUMDISEASE, MICROBIO",

author = "Lim, {Jae Hyang} and Brigid Stirling and Jonathan Derry and Tomoaki Koga and Hirofumi Jono and Woo, {Chang Hoon} and Haodong Xu and Patricia Bourne and Ha, {Un Hwan} and Hajime Ishinaga and Haidong Xu and Ali Andalibi and Feng, {Xin Hua} and Hongguang Zhu and Yuxian Huang and Wenhong Zhang and Xinhua Weng and Chen Yan and Zhinan Yin and Briles, {David E.} and Davis, {Roger J.} and Flavell, {Richard A.} and Li, {Jian Dong}",

note = "Funding Information: We are grateful to Drs. R. Malley and A. Srivastava for kindly providing the purified native PLY and Dr. G. Mosialos for kindly providing anti-CYLD antibody. We also thank Drs. R. Bernards and J. Han for kindly providing various expression plasmids. Out thanks also extend to Dr. R. Malley for his helpful input and discussions regarding the manuscript and Dr. G. Mosialos for critically reviewing this manuscript. This work was supported in part by grants from National Institute of Health DC005843 and DC004562 and a start-up fund from University of Rochester Medical Center (to J.-D.L.), Major State Basic Research (973) Program (2005CB523102), China (to W.Z. and X.W.), Arthritis Foundation Investigator Award, National Institute of Arthritis and Musculoskeltal and Skin Disease Grant KO1 AR 02188, National Institute of Health Grants RO1AI56219 (to Z.Y.), HL077789 and AHA EIA0740021 (to C.Y.) and by Amgen. RJD and RAF are investigators of the Howard Hughes Medical Institute. We declare that a patent on using recombinant PAI-1 for the treatment of lethal bacterial infections has been filed by University of Rochester. ",

year = "2007",

month = aug,

day = "24",

doi = "10.1016/j.immuni.2007.07.011",

language = "English",

volume = "27",

pages = "349--360",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "2",

}

Lim, JH, Stirling, B, Derry, J, Koga, T, Jono, H, Woo, CH, Xu, H, Bourne, P, Ha, UH, Ishinaga, H, Xu, H, Andalibi, A, Feng, XH, Zhu, H, Huang, Y, Zhang, W, Weng, X, Yan, C, Yin, Z, Briles, DE, Davis, RJ, Flavell, RA & Li, JD 2007, 'Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections', Immunity, vol. 27, no. 2, pp. 349-360. https://doi.org/10.1016/j.immuni.2007.07.011

TY - JOUR

T1 - Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections

AU - Lim, Jae Hyang

AU - Stirling, Brigid

AU - Derry, Jonathan

AU - Koga, Tomoaki

AU - Jono, Hirofumi

AU - Woo, Chang Hoon

AU - Xu, Haodong

AU - Bourne, Patricia

AU - Ha, Un Hwan

AU - Ishinaga, Hajime

AU - Xu, Haidong

AU - Andalibi, Ali

AU - Feng, Xin Hua

AU - Zhu, Hongguang

AU - Huang, Yuxian

AU - Zhang, Wenhong

AU - Weng, Xinhua

AU - Yan, Chen

AU - Yin, Zhinan

AU - Briles, David E.

AU - Davis, Roger J.

AU - Flavell, Richard A.

AU - Li, Jian Dong

N1 - Funding Information: We are grateful to Drs. R. Malley and A. Srivastava for kindly providing the purified native PLY and Dr. G. Mosialos for kindly providing anti-CYLD antibody. We also thank Drs. R. Bernards and J. Han for kindly providing various expression plasmids. Out thanks also extend to Dr. R. Malley for his helpful input and discussions regarding the manuscript and Dr. G. Mosialos for critically reviewing this manuscript. This work was supported in part by grants from National Institute of Health DC005843 and DC004562 and a start-up fund from University of Rochester Medical Center (to J.-D.L.), Major State Basic Research (973) Program (2005CB523102), China (to W.Z. and X.W.), Arthritis Foundation Investigator Award, National Institute of Arthritis and Musculoskeltal and Skin Disease Grant KO1 AR 02188, National Institute of Health Grants RO1AI56219 (to Z.Y.), HL077789 and AHA EIA0740021 (to C.Y.) and by Amgen. RJD and RAF are investigators of the Howard Hughes Medical Institute. We declare that a patent on using recombinant PAI-1 for the treatment of lethal bacterial infections has been filed by University of Rochester.

PY - 2007/8/24

Y1 - 2007/8/24

N2 - Streptococcus pneumoniae (S. pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute lung injury (ALI). The molecular mechanisms underlying ALI and the high early mortality remain unknown. Despite recent studies that identify deubiquitinating enzyme cylindromatosis (CYLD) as a key regulator for T cell development, tumor cell proliferation, and NF-κB transcription factor signaling, its role in regulating bacteria-induced lethality, however, is unknown. Here, we showed that CYLD deficiency protected mice from S. pneumoniae pneumolysin (PLY)-induced ALI and lethality. CYLD was highly induced by PLY, and it inhibited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, thereby potentiating ALI and mortality. Thus, CYLD is detrimental for host survival, thereby indicating a mechanism underlying the high early mortality of pneumococcal pneumonia.

AB - Streptococcus pneumoniae (S. pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute lung injury (ALI). The molecular mechanisms underlying ALI and the high early mortality remain unknown. Despite recent studies that identify deubiquitinating enzyme cylindromatosis (CYLD) as a key regulator for T cell development, tumor cell proliferation, and NF-κB transcription factor signaling, its role in regulating bacteria-induced lethality, however, is unknown. Here, we showed that CYLD deficiency protected mice from S. pneumoniae pneumolysin (PLY)-induced ALI and lethality. CYLD was highly induced by PLY, and it inhibited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, thereby potentiating ALI and mortality. Thus, CYLD is detrimental for host survival, thereby indicating a mechanism underlying the high early mortality of pneumococcal pneumonia.

KW - CELLIMMUNO

KW - HUMDISEASE

KW - MICROBIO

UR - http://www.scopus.com/inward/record.url?scp=34548038609&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2007.07.011

DO - 10.1016/j.immuni.2007.07.011

M3 - Article

C2 - 17723219

AN - SCOPUS:34548038609

SN - 1074-7613

VL - 27

SP - 349

EP - 360

JO - Immunity

JF - Immunity

IS - 2

ER -

Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this